Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

GSK and Valeant Receive European Authorisation for Trobalt (retigabine)

March 29, 2011 By Bio-Medicine.Org

LONDON and MISSISSAUGA, Ontario, March 29, 2011 /PRNewswire/ —
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International,
Inc. (NYSE:
VRX
) (TSX: VRX) announced today that the European Commission
has granted marketing authorisation for Trobalt™ (retigabine)
as an adjunctive (add-on) treatment of partial onset seizures (a
form of epilepsy where a seizure begins in a specific area in one
side of the brain), with or without secondary generalisation in
adults aged 18 years and above with epilepsy.(1)

“The European authorisation of retigabine is very welcome as it
will provide neurologists within Europe with a new therapeutic
option for the management of appropriate patients with uncontrolled
partial onset seizures,” said Dr. Tony Hoos, Senior Vice President,
European Medical Affairs, GSK.

This European licence was supported by the results of the
pivotal phase III studies RESTORE 1 and 2, and Study 205, a phase
IIb study. The results of these three studies showed that more
patients with partial onset seizures saw a reduction of 50% or more
in seizure frequency compared to placebo, when a 600mg, 900mg or
1200mg dose of retigabine was added to their current anti-epileptic
drug (AED) therapy.(1)  

In controlled clinical studies with retigabine, urinary
retention occurred at a rate of 0.9 percent in patients receiving
the drug compared to 0.5 percent on placebo. Across the phase
II/III safety population there were four (0.3%) serious adverse
events of urinary retention, three of which were known to have
resulted in withdrawal. The EU prescribing information therefore
recommends that retigabine is used with caution in patients at risk
of urinary retention.(1)

Retigabine also caused a prolongation of the QT interval
(electrical activity of the heart) when used at the highest dose in
healthy volunteers in a thorough QT study. As a precaution,
th

‘/>”/>

SOURCE

Related Articles Read More >

An illustration of Embolization Inc.'s Nitinol Enhanced Device (NED).
This nitinol vascular embolization device has another shape memory material up its sleeve
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
July 2025 edition: The Surgical Robotics issue, featuring Capstan Medical, J&J and Zimmer Biomet
A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe